IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Exclusion Criteria

• •Other active malignancies that require treatment or that might interfere with the trial endpoints (ongoing adjuvant anti-hormonal treatment is allowed)
• •History of hypersensitivity to components of IMA401, CPI treatment or rescue medications, contraindication for pembrolizumab
• •Patients with prior allogeneic stem cell transplantation or organ transplantation
• •Patients with autoimmune diseases needing disease-directed treatment
• •Any serious or uncontrolled health condition, which, in the opinion of the Investigator, would place the subject at undue risk from the study, impair the ability of the subject to receive protocol specified therapy, or interfere with the interpretation of study results
• •Positive for HIV or with active hepatitis B or C infection.
• •Patients with active infection
• •Systemic corticosteroids (≥ 10 mg/day prednisone or equivalent) received 2 weeks prior to starting trial treatment
• •Patients with active central nervous system metastases and leptomeningeal metastases